Clinical trial
A Phase I Clinical Trial Evaluating the Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for Advanced Hepatocellular Carcinoma (HCC)
NCT02814461 is registered in ClinicalTrials.gov with Shin Kong Wu Ho-Su Memorial Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial Evaluating the Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for Advanced Hepatocellular Carcinoma (HCC)
- Lead sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2015
- Completion date
- November 30, 2018
- Enrollment
- 9 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced hepatocellular carcinoma (hcc)